Charalampos Theocharopoulos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Charalampos Theocharopoulos has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Dimitrios C. Ziogas
First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
7 shared publications - Helen Gogas
Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece
7 shared publications - Ioannis Katsaros
First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece
3 shared publications - Stavros P. Papadakos
First Department of Gastroenterology, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece
3 shared publications - Amalia Anastasopoulou
First Department of Internal Medicine, School of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece
2 shared publications - Dimitra Foteinou
First Department of Medicine, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
2 shared publications
Latest Publications
- Open Access
Medical Management of Secreting Syndromes in Functioning Pancreatic Neuroendocrine Tumors: A Scoping Review and Evidence Map
Background: Functioning pancreatic neuroendocrine tumors (pan-NETs) cause syndromes that can be life-threatening. Current guidelines recommend syndrome-directed drugs, but the primary evidence for hormonal control has never been mapped separately from the evidence for antitumor activity. We described how much evidence exists, how it is distributed, what outcomes were measured, and how completely the studies were reported across the ten functioning pan-NET syndromes recognized by the European Neuroendocrine Tumor Society (ENETS). Methods: We followed JBI methodology and PRISMA-ScR. PubMed/MEDLINE, Embase and Cochrane CENTRAL were searched from 1970 onward. Guideline-reference reconciliation, targeted syndrome-by-drug searches, backward citation checking and a date-sliced PubMed update with a clinical-series arm supplemented database searching. Eligible studies included at least three patients with a pancreatic-primary functioning neuroendocrine tumor and an extractable outcome of medical syndrome control. Evidence was charted by syndrome, therapy, design and reporting domain; formal certainty grading and meta-analysis were not undertaken. Results: Sixty-five studies formed the primary corpus. Fifty-three were single-cohort retrospective studies or case series, seven were prospective and five were comparative or multicenter retrospective studies. The median eligible sample was 13 patients among 55 studies with an exact denominator; 25/55 enrolled ten or fewer patients. Insulinoma accounted for 33 studies, followed by VIPoma (13), gastrinoma/Zollinger–Ellison syndrome (12) and glucagonoma (11). PTHrP-mediated hypercalcemia was represented by four studies and the combined ectopic ACTH/CRH category by two, both concerning ACTH secretion; no eligible primary study was identified for calcitoninoma or pancreatic carcinoid syndrome, which indicates the absence of eligible evidence rather than evidence of absent clinical experience. Forty-five out of 80 syndrome-by-therapy cells were empty. Biochemical or physiological outcomes were reported in 58/65 studies and clinical outcomes in 44/65, but definitions varied and the outcomes were not pooled; treatment line was reported in 41/65 and tumor grade in 25/65. A separate inventory contained 321 contextual and secondary records. Conclusions: Medical management of functioning pan-NETs looks well established in daily practice, but the primary evidence behind it is uneven and incompletely reported. The amount of evidence differs sharply between syndromes, and it does not support any comparative treatment sequence. Future studies should measure hormonal control separately from antitumor activity, adopt a core outcome set and a minimum reporting dataset, and use prospective multicenter networks for the rarest syndromes and for the treatment sequences that remain unstudied.
Open AccessMedical Management of Secreting Syndromes in Functioning Pancreatic Neuroendocrine Tumors: A Scoping Review and Evidence Map
Background: Functioning pancreatic neuroendocrine tumors (pan-NETs) cause syndromes that can be life-threatening. Current guidelines recommend syndrome-directed drugs, but the primary evidence for hormonal control has never been mapped separately from the evidence for antitumor activity. We described how much evidence exists, how it is distributed, what outcomes were measured, and how completely the studies were reported across the ten functioning pan-NET syndromes recognized by the European Neuroendocrine Tumor Society (ENETS). Methods: We followed JBI methodology and PRISMA-ScR. PubMed/MEDLINE, Embase and Cochrane CENTRAL were searched from 1970 onward. Guideline-reference reconciliation, targeted syndrome-by-drug searches, backward citation checking and a date-sliced PubMed update with a clinical-series arm supplemented database searching. Eligible studies included at least three patients with a pancreatic-primary functioning neuroendocrine tumor and an extractable outcome of medical syndrome control. Evidence was charted by syndrome, therapy, design and reporting domain; formal certainty grading and meta-analysis were not undertaken. Results: Sixty-five studies formed the primary corpus. Fifty-three were single-cohort retrospective studies or case series, seven were prospective and five were comparative or multicenter retrospective studies. The median eligible sample was 13 patients among 55 studies with an exact denominator; 25/55 enrolled ten or fewer patients. Insulinoma accounted for 33 studies, followed by VIPoma (13), gastrinoma/Zollinger–Ellison syndrome (12) and glucagonoma (11). PTHrP-mediated hypercalcemia was represented by four studies and the combined ectopic ACTH/CRH category by two, both concerning ACTH secretion; no eligible primary study was identified for calcitoninoma or pancreatic carcinoid syndrome, which indicates the absence of eligible evidence rather than evidence of absent clinical experience. Forty-five out of 80 syndrome-by-therapy cells were empty. Biochemical or physiological outcomes were reported in 58/65 studies and clinical outcomes in 44/65, but definitions varied and the outcomes were not pooled; treatment line was reported in 41/65 and tumor grade in 25/65. A separate inventory contained 321 contextual and secondary records. Conclusions: Medical management of functioning pan-NETs looks well established in daily practice, but the primary evidence behind it is uneven and incompletely reported. The amount of evidence differs sharply between syndromes, and it does not support any comparative treatment sequence. Future studies should measure hormonal control separately from antitumor activity, adopt a core outcome set and a minimum reporting dataset, and use prospective multicenter networks for the rarest syndromes and for the treatment sequences that remain unstudied.
- 5 February 2026
- Published by Springer Nature in Current Oncology Reports
- Vol. 28 (1) , 10
Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity
The gut microbiome (GM) has emerged as a pivotal modulator of melanoma pathogenesis and progression through its influence on systemic inflammation, immune surveillance, and antitumor immunity. Inter-individual variability in GM composition may underlie differences in immune checkpoint inhibitor (ICI) responsiveness and the development of immune-related adverse events (irAEs). This review aims to synthesize current knowledge on the complex interplay between the GM, host immunity, and melanoma, emphasizing its relevance to disease development, therapeutic response, and toxicity. Both preclinical and clinical evidence have demonstrated that alterations in microbial diversity and composition can affect melanoma outcomes. Depletion or imbalance of specific microbial taxa has been linked to an increased risk of melanoma development or, conversely, to reduced tumor burden. In patients treated with ICIs, distinct taxonomic GM signatures have been correlated with therapeutic efficacy and the likelihood of developing irAEs. Emerging studies have also explored strategies to modulate the GM-including diet, antibiotics, probiotics, and fecal microbiota transplantation-to restore gut "eubiosis" and enhance antitumor immune responses. The intricate crosstalk between the gut microbiome, host immunity, and melanoma significantly influences disease biology and treatment outcomes. A deeper understanding of these interactions will be critical to the development of microbiome-informed, personalized approaches to melanoma management and immunotherapy optimization.
- 5 February 2026
- Published by Springer Nature in Current Oncology Reports
- Vol. 28 (1) , 10
Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity
The gut microbiome (GM) has emerged as a pivotal modulator of melanoma pathogenesis and progression through its influence on systemic inflammation, immune surveillance, and antitumor immunity. Inter-individual variability in GM composition may underlie differences in immune checkpoint inhibitor (ICI) responsiveness and the development of immune-related adverse events (irAEs). This review aims to synthesize current knowledge on the complex interplay between the GM, host immunity, and melanoma, emphasizing its relevance to disease development, therapeutic response, and toxicity. Both preclinical and clinical evidence have demonstrated that alterations in microbial diversity and composition can affect melanoma outcomes. Depletion or imbalance of specific microbial taxa has been linked to an increased risk of melanoma development or, conversely, to reduced tumor burden. In patients treated with ICIs, distinct taxonomic GM signatures have been correlated with therapeutic efficacy and the likelihood of developing irAEs. Emerging studies have also explored strategies to modulate the GM-including diet, antibiotics, probiotics, and fecal microbiota transplantation-to restore gut "eubiosis" and enhance antitumor immune responses. The intricate crosstalk between the gut microbiome, host immunity, and melanoma significantly influences disease biology and treatment outcomes. A deeper understanding of these interactions will be critical to the development of microbiome-informed, personalized approaches to melanoma management and immunotherapy optimization.
- Open Access
Can CT Radiomics Predict the Ki-67 Index of Gastrointestinal Stromal Tumors (GISTs)? A Systematic Review and Meta-Analysis
Background/Objectives: Computed tomography (CT)-based radiomic analysis is an emerging technique that enables non-invasive assessment of tumor characteristics. In gastrointestinal stromal tumors (GISTs), radiomics may reflect biological behavior such as proliferative activity, often indicated by Ki-67 expression. To our knowledge, this is the first systematic review and meta-analysis synthesizing evidence on the ability of CT radiomics to predict the Ki-67 index in GISTs, addressing an important gap in the literature. Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines to evaluate the predictive performance of CT radiomics for Ki-67 expression in GISTs. A literature search of PubMed, Scopus, Science Direct, and the Cochrane Library was performed up to December 2024 using predefined terms. Extracted data included study design, patient demographics, imaging protocols, radiomic features, and diagnostic performance. Study quality was assessed using the QUADAS-2 tool. A random-effects meta-analysis summarized the pooled area under the ROC curve (AUC), sensitivity, and specificity. Subgroup and sensitivity analyses explored heterogeneity sources. Publication bias was assessed using Egger’s test and funnel plots. Results: Six studies involving 1632 patients were included. The pooled sensitivity and specificity for predicting Ki-67 expression were 0.71 and 0.76, respectively, with a summary AUC of 0.79. Subgroup analyses showed consistent results across different imaging protocols and radiomic feature sets, though the Ki-67 cutoff (8% vs. 10%) affected diagnostic performance. Moderate heterogeneity and potential publication bias in specificity were observed. Conclusions: CT-based radiomics demonstrates moderate accuracy for non-invasively predicting Ki-67 index in GISTs. While not a substitute for histology, it may support personalized preoperative planning and guide future immunotherapy strategies. In the future, radiomic signatures—particularly when integrated with molecular or immune-related biomarkers—could help refine patient selection and monitoring strategies for emerging therapies, including immunotherapy.
Open AccessCan CT Radiomics Predict the Ki-67 Index of Gastrointestinal Stromal Tumors (GISTs)? A Systematic Review and Meta-Analysis
Background/Objectives: Computed tomography (CT)-based radiomic analysis is an emerging technique that enables non-invasive assessment of tumor characteristics. In gastrointestinal stromal tumors (GISTs), radiomics may reflect biological behavior such as proliferative activity, often indicated by Ki-67 expression. To our knowledge, this is the first systematic review and meta-analysis synthesizing evidence on the ability of CT radiomics to predict the Ki-67 index in GISTs, addressing an important gap in the literature. Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines to evaluate the predictive performance of CT radiomics for Ki-67 expression in GISTs. A literature search of PubMed, Scopus, Science Direct, and the Cochrane Library was performed up to December 2024 using predefined terms. Extracted data included study design, patient demographics, imaging protocols, radiomic features, and diagnostic performance. Study quality was assessed using the QUADAS-2 tool. A random-effects meta-analysis summarized the pooled area under the ROC curve (AUC), sensitivity, and specificity. Subgroup and sensitivity analyses explored heterogeneity sources. Publication bias was assessed using Egger’s test and funnel plots. Results: Six studies involving 1632 patients were included. The pooled sensitivity and specificity for predicting Ki-67 expression were 0.71 and 0.76, respectively, with a summary AUC of 0.79. Subgroup analyses showed consistent results across different imaging protocols and radiomic feature sets, though the Ki-67 cutoff (8% vs. 10%) affected diagnostic performance. Moderate heterogeneity and potential publication bias in specificity were observed. Conclusions: CT-based radiomics demonstrates moderate accuracy for non-invasively predicting Ki-67 index in GISTs. While not a substitute for histology, it may support personalized preoperative planning and guide future immunotherapy strategies. In the future, radiomic signatures—particularly when integrated with molecular or immune-related biomarkers—could help refine patient selection and monitoring strategies for emerging therapies, including immunotherapy.
- Open Access
Deep Learning to Enhance Diagnosis and Management of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (iCCA) is associated with a poor prognosis and necessitates a multimodal, multidisciplinary approach from diagnosis to treatment to achieve optimal outcomes. A noninvasive preoperative diagnosis using abdominal imaging techniques can represent a clinical challenge. Given the differential response of iCCA to localized and systemic therapies compared with hepatocellular carcinoma and secondary hepatic malignancies, an accurate diagnosis is crucial. Deep learning (DL) models for image analysis have emerged as a promising adjunct for the abdominal radiologist, potentially enhancing the accurate detection and diagnosis of iCCA. Over the last five years, several reports have proposed robust DL models, which demonstrate a diagnostic accuracy that is either comparable to or surpasses that of radiologists with varying levels of experience. Recent studies have expanded DL applications into other aspects of iCCA management, including histopathologic diagnosis, the prediction of histopathological features, the preoperative prediction of survival, and the pretreatment prediction of responses to systemic therapy. We herein critically evaluate the expanding body of research on DL applications in the diagnosis and management of iCCA, providing insights into the current progress and future research directions. We comprehensively synthesize the performance and limitations of DL models in iCCA research, identifying key challenges that serve as a translational reference for clinicians.
Open AccessDeep Learning to Enhance Diagnosis and Management of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (iCCA) is associated with a poor prognosis and necessitates a multimodal, multidisciplinary approach from diagnosis to treatment to achieve optimal outcomes. A noninvasive preoperative diagnosis using abdominal imaging techniques can represent a clinical challenge. Given the differential response of iCCA to localized and systemic therapies compared with hepatocellular carcinoma and secondary hepatic malignancies, an accurate diagnosis is crucial. Deep learning (DL) models for image analysis have emerged as a promising adjunct for the abdominal radiologist, potentially enhancing the accurate detection and diagnosis of iCCA. Over the last five years, several reports have proposed robust DL models, which demonstrate a diagnostic accuracy that is either comparable to or surpasses that of radiologists with varying levels of experience. Recent studies have expanded DL applications into other aspects of iCCA management, including histopathologic diagnosis, the prediction of histopathological features, the preoperative prediction of survival, and the pretreatment prediction of responses to systemic therapy. We herein critically evaluate the expanding body of research on DL applications in the diagnosis and management of iCCA, providing insights into the current progress and future research directions. We comprehensively synthesize the performance and limitations of DL models in iCCA research, identifying key challenges that serve as a translational reference for clinicians.
- Open Access
- 30 January 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 208, 104635
Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results
- 30 January 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 208, 104635
Open AccessClinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results
- Open Access
Deep Learning for Image Analysis in the Diagnosis and Management of Esophageal Cancer
Esophageal cancer has a dismal prognosis and necessitates a multimodal and multidisciplinary approach from diagnosis to treatment. High-definition white-light endoscopy and histopathological confirmation remain the gold standard for the definitive diagnosis of premalignant and malignant lesions. Artificial intelligence using deep learning (DL) methods for image analysis constitutes a promising adjunct for the clinical endoscopist that could effectively decrease BE overdiagnosis and unnecessary surveillance, while also assisting in the timely detection of dysplastic BE and esophageal cancer. A plethora of studies published during the last five years have consistently reported highly accurate DL algorithms with comparable or superior performance compared to endoscopists. Recent efforts aim to expand DL utilization into further aspects of esophageal neoplasia management including histologic diagnosis, segmentation of gross tumor volume, pretreatment prediction and post-treatment evaluation of patient response to systemic therapy and operative guidance during minimally invasive esophagectomy. Our manuscript serves as an introduction to the growing literature of DL applications for image analysis in the management of esophageal neoplasia, concisely presenting all currently published studies. We also aim to guide the clinician across basic functional principles, evaluation metrics and limitations of DL for image recognition to facilitate the comprehension and critical evaluation of the presented studies.
Open AccessDeep Learning for Image Analysis in the Diagnosis and Management of Esophageal Cancer
Esophageal cancer has a dismal prognosis and necessitates a multimodal and multidisciplinary approach from diagnosis to treatment. High-definition white-light endoscopy and histopathological confirmation remain the gold standard for the definitive diagnosis of premalignant and malignant lesions. Artificial intelligence using deep learning (DL) methods for image analysis constitutes a promising adjunct for the clinical endoscopist that could effectively decrease BE overdiagnosis and unnecessary surveillance, while also assisting in the timely detection of dysplastic BE and esophageal cancer. A plethora of studies published during the last five years have consistently reported highly accurate DL algorithms with comparable or superior performance compared to endoscopists. Recent efforts aim to expand DL utilization into further aspects of esophageal neoplasia management including histologic diagnosis, segmentation of gross tumor volume, pretreatment prediction and post-treatment evaluation of patient response to systemic therapy and operative guidance during minimally invasive esophagectomy. Our manuscript serves as an introduction to the growing literature of DL applications for image analysis in the management of esophageal neoplasia, concisely presenting all currently published studies. We also aim to guide the clinician across basic functional principles, evaluation metrics and limitations of DL for image recognition to facilitate the comprehension and critical evaluation of the presented studies.
- 29 July 2024
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 129, 102806
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?
- 29 July 2024
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 129, 102806
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?
- Open Access
New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3
Immune checkpoints (ICs) are molecules implicated in the fine-tuning of immune response via co-inhibitory or co-stimulatory signals, and serve to secure minimized host damage. Targeting ICs with various therapeutic modalities, including checkpoint inhibitors/monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and CAR-T cells has produced remarkable results, especially in immunogenic tumors, setting a paradigm shift in cancer therapeutics through the incorporation of these IC-targeted treatments. However, the large proportion of subjects who experience primary or secondary resistance to available IC-targeted options necessitates further advancements that render immunotherapy beneficial for a larger patient pool with longer duration of response. B7-H3 (B7 Homolog 3 Protein, CD276) is a member of the B7 family of IC proteins that exerts pleiotropic immunomodulatory effects both in physiologic and pathologic contexts. Mounting evidence has demonstrated an aberrant expression of B7-H3 in various solid malignancies, including tumors less sensitive to current immunotherapeutic options, and has associated its expression with advanced disease, worse patient survival and impaired response to IC-based regimens. Anti-B7-H3 agents, including novel mAbs, bispecific antibodies, ADCs, CAR-T cells, and radioimmunotherapy agents, have exhibited encouraging antitumor activity in preclinical models and have recently entered clinical testing for several cancer types. In the present review, we concisely present the functional implications of B7-H3 and discuss the latest evidence regarding its prognostic significance and therapeutic potential in solid malignancies, with emphasis on anti-B7-H3 modalities that are currently evaluated in clinical trial settings. Better understanding of B7-H3 intricate interactions in the tumor microenvironment will expand the oncological utility of anti-B7-H3 agents and further shape their role in cancer therapeutics.
Open AccessNew Emerging Targets in Cancer Immunotherapy: The Role of B7-H3
Immune checkpoints (ICs) are molecules implicated in the fine-tuning of immune response via co-inhibitory or co-stimulatory signals, and serve to secure minimized host damage. Targeting ICs with various therapeutic modalities, including checkpoint inhibitors/monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and CAR-T cells has produced remarkable results, especially in immunogenic tumors, setting a paradigm shift in cancer therapeutics through the incorporation of these IC-targeted treatments. However, the large proportion of subjects who experience primary or secondary resistance to available IC-targeted options necessitates further advancements that render immunotherapy beneficial for a larger patient pool with longer duration of response. B7-H3 (B7 Homolog 3 Protein, CD276) is a member of the B7 family of IC proteins that exerts pleiotropic immunomodulatory effects both in physiologic and pathologic contexts. Mounting evidence has demonstrated an aberrant expression of B7-H3 in various solid malignancies, including tumors less sensitive to current immunotherapeutic options, and has associated its expression with advanced disease, worse patient survival and impaired response to IC-based regimens. Anti-B7-H3 agents, including novel mAbs, bispecific antibodies, ADCs, CAR-T cells, and radioimmunotherapy agents, have exhibited encouraging antitumor activity in preclinical models and have recently entered clinical testing for several cancer types. In the present review, we concisely present the functional implications of B7-H3 and discuss the latest evidence regarding its prognostic significance and therapeutic potential in solid malignancies, with emphasis on anti-B7-H3 modalities that are currently evaluated in clinical trial settings. Better understanding of B7-H3 intricate interactions in the tumor microenvironment will expand the oncological utility of anti-B7-H3 agents and further shape their role in cancer therapeutics.
- Open Access
Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction
Despite ongoing oncological advances, pancreatic ductal adenocarcinoma (PDAC) continues to have an extremely poor prognosis with limited targeted and immunotherapeutic options. Its genomic background has not been fully characterized yet in large-scale populations all over the world. Methods: Replicating a recent study from China, we collected tissue samples from consecutive Greek patients with pathologically-confirmed metastatic/unresectable PDAC and retrospectively investigated their genomic landscape using next generation sequencing (NGS). Findings: From a cohort of 409 patients, NGS analysis was successfully achieved in 400 cases (56.50% males, median age: 61.8 years). Consistent with a previous study, KRAS was the most frequently mutated gene in 81.50% of tested samples, followed by TP53 (50.75%), CDKN2 (8%), and SMAD4 (7.50%). BRCA1/2 variants with on-label indications were detected in 2%, and 87.50% carried a variant associated with off-label treatment (KRAS, ERBB2, STK11, or HRR-genes), while 3.5% of the alterations had unknown/preliminary-studied actionability (TP53/CDKN2A). Most of HRR-alterations were in intermediate- and low-risk genes (CHEK2, RAD50, RAD51, ATM, FANCA, FANCL, FANCC, BAP1), with controversial actionability: 8% harbored a somatic non-BRCA1/2 alteration, 6 cases had a high-risk alteration (PALB2, RAD51C), and one co-presented a PALB2/BRCA2 alteration. Elevated LOH was associated with HRR-mutated status and TP53 mutations while lowered LOH was associated with KRAS alterations. Including TMB/MSI data, the potential benefit from an NGS-oriented treatment was increased from 1.91% to 13.74% (high-MSI: 0.3%, TMB > 10 muts/MB: 12.78%). TMB was slightly increased in females (4.75 vs. 4.46 muts/MB) and in individuals with age > 60 (4.77 vs. 4.40 muts/MB). About 28.41% showed PD-L1 > 1% either in tumor or immune cells, 15.75% expressed PD-L1 ≥ 10%, and only 1.18% had PD-L1 ≥ 50%. This is the largest depiction of real-world genomic characteristics of European patients with PDAC, which offers some useful clinical and research insights.
Open AccessDigging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction
Despite ongoing oncological advances, pancreatic ductal adenocarcinoma (PDAC) continues to have an extremely poor prognosis with limited targeted and immunotherapeutic options. Its genomic background has not been fully characterized yet in large-scale populations all over the world. Methods: Replicating a recent study from China, we collected tissue samples from consecutive Greek patients with pathologically-confirmed metastatic/unresectable PDAC and retrospectively investigated their genomic landscape using next generation sequencing (NGS). Findings: From a cohort of 409 patients, NGS analysis was successfully achieved in 400 cases (56.50% males, median age: 61.8 years). Consistent with a previous study, KRAS was the most frequently mutated gene in 81.50% of tested samples, followed by TP53 (50.75%), CDKN2 (8%), and SMAD4 (7.50%). BRCA1/2 variants with on-label indications were detected in 2%, and 87.50% carried a variant associated with off-label treatment (KRAS, ERBB2, STK11, or HRR-genes), while 3.5% of the alterations had unknown/preliminary-studied actionability (TP53/CDKN2A). Most of HRR-alterations were in intermediate- and low-risk genes (CHEK2, RAD50, RAD51, ATM, FANCA, FANCL, FANCC, BAP1), with controversial actionability: 8% harbored a somatic non-BRCA1/2 alteration, 6 cases had a high-risk alteration (PALB2, RAD51C), and one co-presented a PALB2/BRCA2 alteration. Elevated LOH was associated with HRR-mutated status and TP53 mutations while lowered LOH was associated with KRAS alterations. Including TMB/MSI data, the potential benefit from an NGS-oriented treatment was increased from 1.91% to 13.74% (high-MSI: 0.3%, TMB > 10 muts/MB: 12.78%). TMB was slightly increased in females (4.75 vs. 4.46 muts/MB) and in individuals with age > 60 (4.77 vs. 4.40 muts/MB). About 28.41% showed PD-L1 > 1% either in tumor or immune cells, 15.75% expressed PD-L1 ≥ 10%, and only 1.18% had PD-L1 ≥ 50%. This is the largest depiction of real-world genomic characteristics of European patients with PDAC, which offers some useful clinical and research insights.
- Open Access
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
More than ten years after the approval of ipilimumab, immune checkpoint inhibitors (ICIs) against PD-1 and CTLA-4 have been established as the most effective treatment for locally advanced or metastatic melanoma, achieving durable responses either as monotherapies or in combinatorial regimens. However, a considerable proportion of patients do not respond or experience early relapse, due to multiple parameters that contribute to melanoma resistance. The expression of other immune checkpoints beyond the PD-1 and CTLA-4 molecules remains a major mechanism of immune evasion. The recent approval of anti-LAG-3 ICI, relatlimab, in combination with nivolumab for metastatic disease, has capitalized on the extensive research in the field and has highlighted the potential for further improvement of melanoma prognosis by synergistically blocking additional immune targets with new ICI-doublets, antibody–drug conjugates, or other novel modalities. Herein, we provide a comprehensive overview of presently published immune checkpoint molecules, including LAG-3, TIGIT, TIM-3, VISTA, IDO1/IDO2/TDO, CD27/CD70, CD39/73, HVEM/BTLA/CD160 and B7-H3. Beginning from their immunomodulatory properties as co-inhibitory or co-stimulatory receptors, we present all therapeutic modalities targeting these molecules that have been tested in melanoma treatment either in preclinical or clinical settings. Better understanding of the checkpoint-mediated crosstalk between melanoma and immune effector cells is essential for generating more effective strategies with augmented immune response.
Open AccessBeyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
More than ten years after the approval of ipilimumab, immune checkpoint inhibitors (ICIs) against PD-1 and CTLA-4 have been established as the most effective treatment for locally advanced or metastatic melanoma, achieving durable responses either as monotherapies or in combinatorial regimens. However, a considerable proportion of patients do not respond or experience early relapse, due to multiple parameters that contribute to melanoma resistance. The expression of other immune checkpoints beyond the PD-1 and CTLA-4 molecules remains a major mechanism of immune evasion. The recent approval of anti-LAG-3 ICI, relatlimab, in combination with nivolumab for metastatic disease, has capitalized on the extensive research in the field and has highlighted the potential for further improvement of melanoma prognosis by synergistically blocking additional immune targets with new ICI-doublets, antibody–drug conjugates, or other novel modalities. Herein, we provide a comprehensive overview of presently published immune checkpoint molecules, including LAG-3, TIGIT, TIM-3, VISTA, IDO1/IDO2/TDO, CD27/CD70, CD39/73, HVEM/BTLA/CD160 and B7-H3. Beginning from their immunomodulatory properties as co-inhibitory or co-stimulatory receptors, we present all therapeutic modalities targeting these molecules that have been tested in melanoma treatment either in preclinical or clinical settings. Better understanding of the checkpoint-mediated crosstalk between melanoma and immune effector cells is essential for generating more effective strategies with augmented immune response.